t(5;12)(q23-31;p13) with ETV6-ACSL6 gene fusion in polycythemia vera Leukemia (2006) Myeloproliferative disorders (MPD) are chronic clonal proliferations of hematopoietic progenitors. Typical MPDs include chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IF). Oncogenic alterations identified so far in MPDs target tyrosine kinases, result from chromosomal translocations or gene mutations and lead to constitutive activation of survival and proliferation pathways. Reciprocal translocations lead to gene fusion and production of chimeric proteins such as BCR-ABL, ETV6-PDGFRB or PCM1-JAK2. 1, 2 Point mutations of the JAK2 kinase occur in almost all PV, and in around half of ET and IF.
3 JAK2 functions downstream of membrane receptors, including cytokine receptors such as interleukin-3 (IL3) receptors. Overproduction of IL3 has been reported in atypical CML following rearrangements of the IL3 gene upstream region in cells from patients with t(5;12)(q23-31;p13) translocation and ETV6-ACSL6 fusion. [4] [5] [6] [7] We report here two cases of t(5;12)(q23-31;p13) translocation with ETV6-ACSL6 rearrangement in PV patients. The main characteristics of the two patients (designated C1, C2) are reported in Table 1 , along with the cases reported so far. [4] [5] [6] [7] Patient C1, a 29-year-old man, presented in October 2002 with midly enlarged liver and spleen, effort dyspnea, and polycythemia with 59.7% hematocrit level. The bone marrow (BM) was hypercellular, with rare dystrophic megakaryocytes and 6% eosinophils, without basophilia. Isotopic exploration showed an increased total red blood cell mass. Cytogenetic analysis with R-banding technique on BM cells detected a t(5;12)(q23-31;p13) translocation in three metaphases among 24 analyzed (13%) ( Table 1 ). The patient was treated by phlebotomy but dyspnea persisted, and prurit, paresthesia and headaches appeared. Three months later, a treatment by hydroxyurea was started. Bone marrow showed dystrophic megakaryocytes of the PV type. In May 2005, BM analysis showed increased eosinophilia (16%) and basophilia (10%), and on karyotype, four metaphases among 20 (20%) showed the t(5;12) translocation. In January 2006, 3.5 years after diagnosis, the patient is alive under hydroxyurea treatment, the white blood cell count is 9.6 Â 10 9 /l with 15% eosinophils and 15% basophils, hemoglobin level 16.5 and platelet count 484 Â 10 9 /l. The indication of allogenic transplantation is under discussion.
Patient C2, a 31-year-old woman, presented in 1979 with PV. She was treated by phlebotomy and splenic irradiation. In 1998, because of an important splenomegaly, a second splenic part of ETV6 at 12p13.2, revealed in red, TRITC); (c) biotinylated RP11-75N23 (5 0 part of ETV6, revealed in green, FITC) in combination with digoxigenin-labeled centromeric probe and RP11-60O5 (IL3 and CSF2 at 5q23.3) (both revealed in red, TRITC). Separation of RP11-345H15 and RP11-60O5 on der(5) and der (12), respectively (a,c) suggests that the 5q23 breakpoint targets the 5 0 region of ACSL6. The 12p13 breakpoint targeting ETV6 is characterized by the split red signal of RP11-418C2 on the der(5) and der(12) (b). (d-g) Normal locus organization (d, e) based on UCSC Genome Browser, and new genomic organization created by t(5;12) on derivative chromosomes (f, g). On the der(12) (g), the IL3 locus is transposed in the vicinity of ETV6 sequences in an opposite orientation.
Letter to the editor 20% blasts. At this time, the karyotype was a failure. The patient died from hemorrhagic syndrome.
Analysis of the t(5;12) showed that the breakpoint on chromosome arm 5q was centromeric to q33. This led us to suspect an ETV6-ACSL6 fusion rather than an ETV6-PDGFRB fusion. We demonstrated the involvement of ETV6 and the 5 0 region of ACSL6 (previously ACS2) in the translocation by using dual-color fluorescence in situ hybridization (FISH) on metaphases of MPD cells from patient C1, using labeled BAC clones, as previously described. 8 BACs were obtained from the BACPAC resource (Children's Hospital Oakland-BACPAC Resources, Oakland, CA, USA). Genomic information was obtained from the UCSC Genome Browser on Human, May 2004 Assembly, which is based on NCBI Build 35 (National Center for Biotechnology Information, Bethesda, MD, USA), http://genome.ucsc.edu/). The 12p13 breakpoint was characterized with BAC clones, from centromere to telomere, RP11-75N23 (included in NT_009714; chr12:11,547,904-11,699,895) and RP11-418C2 (AC084358; chr12:11,807,596-11,977,544) covering 5 0 part and intron 3-3 0 part of ETV6, respectively (Figure 1  a-c) . RP11-418C2 showed signals on normal chromosome 12, and derivative chromosomes 12 and 5, suggesting that the 12p13 breakpoint spanned ETV6 gene. RP11-75N23 showed signals on derivative chromosome 5 and normal chromosome 12, in agreement with ETV6 5 0 -3 0 orientation and telomerecentromere chromosomal direction. The 5q23 breakpoint was characterized by using two contiguous BAC clones, from centromere to telomere, RP11-345H15 (included in NT_034772; chr5:131,228,858-131,399,683) and RP11-60O5 (included in NT_034772; chr5:131,383,516-131,534,725 containing mainly ACSL6, and IL3 and ACSL6 genes, respectively). RP11-904M10 (AC021049; chr12:10,618,160-10,793,439) specific for STYK1 (12p13) and telomeric to ETV6 was used as control to distinguish chromosome derivative 5. Both RP11-345H15 and RP11-60O5 showed hybridization signals on normal chromosome 5. RP11-345H15 was also present on derivative chromosome 5. RP11-60O5 was detected only on derivative chromosome 12, suggesting that the breakpoint was located in the 5 0 region of ACSL6. The new genomic organization created by the event is shown in Figure 1d -g. Unfortunately, the RNA material was not available to look for the presence of the ETV6-ACSL6 fusion transcript.
We determined the status of the JAK2 kinase in patient C1 by sequencing DNA from peripheral blood cells in January 2006 using published procedure and an ABI3100 apparatus (reviewed by Tefferi and Gilliland 3 ). The Val617Phe mutation was not found (not shown).
In conclusion, we have described a genomic alteration that had never been described before in PV patients. As suggested, 4 the result of the rearrangement could be an upregulation of the IL3 gene. Owing to the orientation of the rearranged genes on the der(12), it is probable that the cause of this upregulation is a chromatin conformation change rather than an ETV6 promoter effect. In one of the patients, the sequencing of blood cells DNA failed to show a JAK2 mutation. Two explanations may be proposed. First, because the t(5;12) is present only in 20% of mitoses, the JAK2 mutation could be present in the same clone but not detected by our DNA analysis although its measured sensitivity was below this range; in this case, the translocation would appear as a secondary event. Eosinophilia was detected in patient A2 only at the second relapse, concomitantly with the occurrence of the t(5;12). 5 Alternatively, increased level of IL3 due to the rearrangement may enhance non-mutated JAK2 activity and trigger PV, eosinophilia and basophilia, and may eventually lead to acute transformation of the translocated clone. If this is the case, genomic events such as a t(5;12) rearrangement may account for few JAK2-negative PV. 
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